Papp 2003 (P).

Methods	DESIGN Between‐patient Participant delivery ALLOCATION Random Method of randomisation: computer‐generated random code Concealment: adequate BLINDING Double‐blind (participant/investigator) WITHDRAWAL/DROPOUT Described
Participants	N: 1043 Treatment duration: 4 wks; FU: 4 wks LF: 15 (1.4%) BC: yes Age: 47.1 Gender (per cent men): 58.4% Severity: mean PASI = 10.8 (range = 1 to 36) Duration: 18.7 years INCLUSION CRITERIA Chronic plaque psoriasis Aged at least 18 BSA ≥10% EXCLUSION CRITERIA Other types of psoriasis or skin diseases Hypercalcaemia Systemic antipsoriatic treatment or UV therapy within previous 6 wks Topical antipsoriatic therapy within previous 2 wks Other concomitant medication that might affect psoriasis Contraindications for corticosteroid treatment Planned exposure to UV light Pregnancy Lactation
Interventions	Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination ointment BD (D) Calcipotriol 50 mcg/g in combination vehicle ointment BD (C) Betamethasone dipropionate 0.5 mg/g in combination vehicle ointment BD (B) Placebo (combination vehicle) ointment BD (P)
Outcomes	PASI (head excluded) Total Severity Score (9‐pt, absent to very severe) IAGI (6‐pt: worse to clearance) PAGI (6‐pt: worse to clearance)
Notes	Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Treatments were assigned by computer‐generated code and assigned chronologically at each centre.
Blinding (performance bias and detection bias) All outcomes	Low risk	The trial was double‐blind (participant/investigator), and treatments were identifiable only by a code number.
Randomisation method reported	Low risk	Randomisation was computer‐generated. (3:3:3:1)
Loss to follow up	Low risk	1.4%
Baseline assessments	Low risk	‐
Baseline comparability demonstrated	Low risk	‐